AMI Asset Management Corp Invests $1.28 Million in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

AMI Asset Management Corp bought a new stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 51,262 shares of the company's stock, valued at approximately $1,281,000. AMI Asset Management Corp owned approximately 0.07% of Kiniksa Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Acadian Asset Management LLC lifted its holdings in shares of Kiniksa Pharmaceuticals by 167.8% in the first quarter. Acadian Asset Management LLC now owns 164,568 shares of the company's stock valued at $3,240,000 after buying an additional 103,120 shares during the period. Sei Investments Co. acquired a new stake in Kiniksa Pharmaceuticals in the 1st quarter valued at about $1,450,000. Dimensional Fund Advisors LP boosted its position in shares of Kiniksa Pharmaceuticals by 31.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company's stock valued at $12,398,000 after purchasing an additional 157,741 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of Kiniksa Pharmaceuticals by 8.1% in the 1st quarter. SG Americas Securities LLC now owns 19,160 shares of the company's stock worth $378,000 after purchasing an additional 1,435 shares during the last quarter. Finally, Millennium Management LLC grew its stake in shares of Kiniksa Pharmaceuticals by 159.8% in the 2nd quarter. Millennium Management LLC now owns 621,948 shares of the company's stock worth $11,612,000 after purchasing an additional 382,539 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals Stock Performance

Shares of NASDAQ KNSA traded down $0.25 during mid-day trading on Wednesday, reaching $23.01. The company had a trading volume of 357,720 shares, compared to its average volume of 412,508. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of -143.81 and a beta of 0.33. The stock has a fifty day moving average of $25.57 and a two-hundred day moving average of $22.42. Kiniksa Pharmaceuticals, Ltd. has a 12-month low of $14.12 and a 12-month high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative return on equity of 7.79% and a negative net margin of 3.10%. The company had revenue of $112.21 million during the quarter, compared to analyst estimates of $111.51 million. During the same period last year, the company posted ($0.20) earnings per share. The company's revenue was up 67.4% compared to the same quarter last year. Sell-side analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.29 earnings per share for the current fiscal year.

Insider Activity at Kiniksa Pharmaceuticals

In other news, COO Eben Tessari sold 17,500 shares of the firm's stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $26.91, for a total transaction of $470,925.00. Following the transaction, the chief operating officer now owns 119,911 shares in the company, valued at approximately $3,226,805.01. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, COO Eben Tessari sold 17,500 shares of the company's stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $26.91, for a total transaction of $470,925.00. Following the completion of the sale, the chief operating officer now owns 119,911 shares in the company, valued at approximately $3,226,805.01. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider John F. Paolini sold 60,692 shares of the firm's stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $26.12, for a total value of $1,585,275.04. Following the completion of the transaction, the insider now directly owns 52,038 shares in the company, valued at $1,359,232.56. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 112,692 shares of company stock valued at $2,950,315. 54.57% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

KNSA has been the subject of a number of research reports. Wedbush raised their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an "outperform" rating in a report on Tuesday, July 23rd. Jefferies Financial Group initiated coverage on Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They set a "buy" rating and a $40.00 price objective for the company. Finally, Evercore ISI lifted their target price on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an "outperform" rating in a report on Wednesday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals currently has an average rating of "Buy" and an average price target of $34.60.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.